Dual NAT Reuptake/H3 Receptor Antagonists (Angita)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameDual NAT Reuptake/H3 Receptor Antagonists (Angita)
Drug Alias Namedual NAT reuptake/H3 receptor antagonists (Angita)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H3 receptor antagonists
TargetsHistamine H3 receptor
Therapy Area/IndicationsCognition Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAngita Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAngita Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsCognition Disorders

Other Information

ATC CodeN/A
Related LinksN/A